Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiXET: Fixed Dose Enoxaparin in Neonates and Children With Thrombosis
NCT02486666Phase 3Unknown
- Sponsor
- Hamilton Health Sciences
- Start
- Mar 2016
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Feasibility of recruiting at least 5 subjects per center and Safety of administering weight adjusted fixed dose enoxaparin. Status: unknown.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02486666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486666.